Influence of growth and metabolic markers on hs-troponin T and NT-proBNP levels in healthy children.
NT-proBNP
cardiac biomarkers
growth factors
pediatric percentiles
troponin T
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
01 Oct 2023
01 Oct 2023
Historique:
received:
02
04
2023
accepted:
10
08
2023
medline:
10
8
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
epublish
Résumé
As part of the LIFE Child study, we previously described the associations between N-terminal-pro-hormone brain natriuretic peptide (NT-proBNP) and hs-troponin T (hs-TnT) levels and an individual's sex, age and pubertal status, as well as with body mass index (BMI) and serum lipid levels. For NT-proBNP, we found inverse associations with advancing puberty, increasing BMI and serum lipid levels. These findings led us to further question the putative influences of the developing individual's metabolic and growth status as represented by levels of insulin-like growth factor-1 (IGF-1) and IGF-1-binding protein-3 (IGF-BP3) as well as hemoglobin A1c (HbA1c) and Cystatin C (CysC). Serum values, medical history and anthropometric data provided by 2522 children aged 0.25-18 years were collected and analyzed as per study protocol. A strong negative association between NT-proBNP values and IGF-1, IGF-BP3 and HbA1c levels was identified. For IGF-BP3, this interaction was modulated by sex and age, for HbA1c only by age. For hs-TnT, a positive association was found with IGF-BP3, IGF-1 and CysC. The association between hs-TnT and IGF-1 was sex dependent. The association between CysC and hs-TnT was stronger in girls, but the interaction with age was only seen in boys. Between hs-TnT and HbA1c, the association was significantly negative and modulated by age. Based on our large pediatric cohort, we could identify age- and sex-dependent interactions between the metabolic status represented by IGF-1, IGF-BP3, CysC and HbA1c levels and the cardiac markers NT-proBNP and hs-TnT.
Sections du résumé
Background and objectives
UNASSIGNED
As part of the LIFE Child study, we previously described the associations between N-terminal-pro-hormone brain natriuretic peptide (NT-proBNP) and hs-troponin T (hs-TnT) levels and an individual's sex, age and pubertal status, as well as with body mass index (BMI) and serum lipid levels. For NT-proBNP, we found inverse associations with advancing puberty, increasing BMI and serum lipid levels. These findings led us to further question the putative influences of the developing individual's metabolic and growth status as represented by levels of insulin-like growth factor-1 (IGF-1) and IGF-1-binding protein-3 (IGF-BP3) as well as hemoglobin A1c (HbA1c) and Cystatin C (CysC).
Material and methods
UNASSIGNED
Serum values, medical history and anthropometric data provided by 2522 children aged 0.25-18 years were collected and analyzed as per study protocol.
Results
UNASSIGNED
A strong negative association between NT-proBNP values and IGF-1, IGF-BP3 and HbA1c levels was identified. For IGF-BP3, this interaction was modulated by sex and age, for HbA1c only by age. For hs-TnT, a positive association was found with IGF-BP3, IGF-1 and CysC. The association between hs-TnT and IGF-1 was sex dependent. The association between CysC and hs-TnT was stronger in girls, but the interaction with age was only seen in boys. Between hs-TnT and HbA1c, the association was significantly negative and modulated by age.
Conclusion
UNASSIGNED
Based on our large pediatric cohort, we could identify age- and sex-dependent interactions between the metabolic status represented by IGF-1, IGF-BP3, CysC and HbA1c levels and the cardiac markers NT-proBNP and hs-TnT.
Identifiants
pubmed: 37561076
doi: 10.1530/EC-23-0120
pii: EC-23-0120
pmc: PMC10563603
doi:
pii:
Types de publication
Journal Article
Langues
eng
Références
Peptides. 2019 Jan;111:18-25
pubmed: 29859763
Eur J Clin Invest. 2016 Sep;46(9):795-803
pubmed: 27455178
J Clin Endocrinol Metab. 2022 Jun 16;107(7):e2991-e3002
pubmed: 35294528
J Endocrinol Invest. 2008 Mar;31(3):196-200
pubmed: 18401200
J Pediatr. 1997 Jul;131(1 Pt 2):S70-4
pubmed: 9255233
J Heart Lung Transplant. 2006 Jul;25(7):772-7
pubmed: 16818119
Growth Horm IGF Res. 2003 Aug;13(4):113-70
pubmed: 12914749
Pediatr Cardiol. 2022 Jun;43(5):1071-1083
pubmed: 35277733
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Ann Intern Med. 2003 Oct 21;139(8):642-8
pubmed: 14568852
Am J Cardiol. 2015 Mar 15;115(6):816-20
pubmed: 25616534
J Pediatr Endocrinol Metab. 2002 Jun;15(6):851-2
pubmed: 12099396
Eur J Endocrinol. 2009 Jan;160(1):25-31
pubmed: 18931092
Eur J Endocrinol. 2020 Jan;182(1):79-90
pubmed: 31705797
Hypertension. 1995 Dec;26(6 Pt 1):979-83
pubmed: 7490158
Pituitary. 2010 Dec;13(4):329-36
pubmed: 20697818
Crit Care Med. 1996 Sep;24(9):1460-6
pubmed: 8797616
Endocrine. 2015 Feb;48(1):25-35
pubmed: 24972804
BMC Public Health. 2012 Nov 22;12:1021
pubmed: 23181778
Pediatr Diabetes. 2022 Mar;23(2):194-202
pubmed: 34877761
Nat Rev Cardiol. 2017 Aug;14(8):472-483
pubmed: 28383022
Eur J Epidemiol. 2017 Feb;32(2):145-158
pubmed: 28144813
Crit Care Med. 2001 Jun;29(6):1234-8
pubmed: 11395611
Zhongguo Dang Dai Er Ke Za Zhi. 2013 Apr;15(4):277-80
pubmed: 23607950
Eur J Endocrinol. 2013 Jan 17;168(2):177-84
pubmed: 23132698
Pediatr Nephrol. 2019 Mar;34(3):449-457
pubmed: 30460495
Front Cardiovasc Med. 2022 Jan 21;8:772105
pubmed: 35127852